At its meeting on 4 July 2022 the Transparency Council adopted Position No. 61/2022 on the evaluation of the drug Ilaris (canacinumabum) under the drug programme: “Treatment of congenital autoinflammatory syndromes (ICD-10 E85, R50.9, D89.8, D89.9)”.